TAUG - Tauriga Sciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0167
0.0000 (0.00%)
As of 9:36AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.0167
Open0.0251
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0167 - 0.0251
52 Week Range0.0132 - 1.0000
Volume33,401
Avg. Volume108,968
Market Cap937,374
Beta (3Y Monthly)1.90
PE Ratio (TTM)0.76
EPS (TTM)0.0220
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.10
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    Tauriga Sciences Inc. to Register Trademark with USPTO to Support Launch of its Cannabis Infused Chewing Gum Product Line

    New York, NY, Dec. 07, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (TAUG) (“Tauriga” or the “Company”), engaged in building its business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that the Company is in the process of registering a trademark with the United States Patent & Trademark Office (“USPTO”) to support the upcoming launch of its proposed Cannabis and/or Cannabidiol (“CBD”) chewing gum product line.  Once this above-referenced trademark is granted, the Company will disclose the name under which it will brand this product line.

  • GlobeNewswire14 days ago

    Tauriga Sciences Inc. to Proceed in Development and Launch of Cannabis Infused Chewing Gum Product Line

    New York, NY, Nov. 29, 2018 -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (TAUG) (“Tauriga” or the “Company”), engaged in building its business through the development,.

  • GlobeNewswire2 months ago

    Tauriga Sciences Inc. Completes Capital Raise of $168,250 to Support its Merger & Acquisition Activities

    New York, NY, Oct. 26, 2018 -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (TAUG) (“Tauriga” or the “Company”), engaged in building its business through the development,.

  • GlobeNewswire2 months ago

    Tauriga Sciences Inc. Reaches Agreements to Retire the Remainder of its Outstanding Convertible Debt

    New York, Oct. 25, 2018 -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (TAUG) (“Tauriga” or the “Company”), engaged in building its business through the development,.

  • GlobeNewswire2 months ago

    Tauriga Sciences Inc. Enters into MOU to Acquire California Based Revenue Generating OMEGA-3 Product and Technology

    Los Angeles, CA, Oct. 04, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (TAUG) (“Tauriga” or the “Company”), engaged in building its business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that the Company has entered into a Memorandum of Understanding (“MOU”) to acquire a California based revenue generating OMEGA-3 product and technology.  This MOU, executed on October 3, 2018 (between Tauriga Sciences, Inc. and Malibu Health Technologies), is valid for a period of 45 days and closing is subject to satisfactory completion of due diligence by all parties. Should this proposed transaction successfully be completed, Tauriga expects to proceed in the filing of intellectual property (“IP” or “patents”) pertaining to the above-mentioned molecular distillation technology.  The Company believes that such patent(s) may be relevant to the pharmaceutical industry and therefore could be of significant importance.